As previously disclosed, MitoCareX's broad structural analysis identified a set of SLC transport proteins outside its mitochondrial program that appeared compatible with the MITOLINE® enabled structural modelling. Building on that work, the Company has now completed an internal prioritization process and identified a candidate supported by favorable characteristics for inclusion in a drug discovery campaign.

"This step reflects continued execution of our drug discovery strategy and tangible progress in translating the breadth of our platform into a focused, actionable pipeline decision," said David Palach, Chief Executive Officer of Nexentis Technologies Inc. "Having previously mapped a broader universe of transport protein candidates, we have now taken the next step of narrowing that pool to a priority candidate. We view this as an important example of how MITOLINE® can systematically convert computational insight into concrete discovery decisions over time."